Company intelligence / Profile preview

CymaBay Therapeutics

Newark, California, United Statesgilead.com ↗

Ownership: Public · CBAY
Employees: ~101
Development stage: NDA

Overview

CymaBay’s lead asset seladelpar demonstrated statistically significant improvements over placebo in the pivotal Phase III RESPONSE trial for primary biliary cholangitis—including biochemical response rates and normalization of alkaline phosphatase at one year. Seladelpar also showed significant improvement in pruritus among patients with moderate-to-severe itch. The drug received FDA priority review status prior to the company’s acquisition by Gilead Sciences. Analysts expect it to become a therapy of choice for second-line treatment of PBC due to its efficacy profile and impact on quality-of-life symptoms like pruritus

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Small molecules (notably selective PPARδ agonists such as seladelpar/MBX‑8025)
Industry: Biotech

Drug pipeline

1 asset

seladelpar

NDA

Indications: Primary biliary cholangitis

Partnerships

Johnson & Johnson licensed seladelpar to CymaBay; J&J will receive royalties if approved/sold.No other major partnerships disclosed.

Financials

Market cap: $3.7B
Total revenue: $57K
Enterprise value: $3.4B

Beyond the preview

Go deeper on CymaBay Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CymaBay Therapeutics.

Explore the full profile